EPRX

Eupraxia Pharmaceuticals

14 hedge funds and large institutions have $10.9M invested in Eupraxia Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 0 closing their positions.

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
6
Reduced
5
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
SC
1
Scotia Capital
Ontario, Canada
$6.98M 1,291,989 -260,690 -17%
Royal Bank of Canada
2
Royal Bank of Canada
Ontario, Canada
$2.47M 428,584 +85,756 +25%
Goldman Sachs
3
Goldman Sachs
New York
$229K 39,800 +5,300 +15%
UBS Group
4
UBS Group
Switzerland
$216K 37,499 -13,700 -27%
Bank of Montreal
5
Bank of Montreal
Ontario, Canada
$215K 37,250 -15,000 -29%
ISL
6
Ingalls & Snyder LLC
New York
$214K 37,200 +37,200 New
Citadel Advisors
7
Citadel Advisors
Florida
$108K 18,236 +6,182 +51%
JPMorgan Chase & Co
8
JPMorgan Chase & Co
New York
$108K 18,717 +16,017 +593%
CIBC World Market
9
CIBC World Market
Ontario, Canada
$86.4K 15,000 +15,000 New
Bank of America
10
Bank of America
North Carolina
$72.3K 12,559 +10,059 +402%
Raymond James Financial
11
Raymond James Financial
Florida
$70.3K 12,212 +1,079 +10%
QC
12
Quadrature Capital
United Kingdom
$61.4K 10,700 +10,700 New
TWC
13
TD Waterhouse Canada
Ontario, Canada
$55.9K 9,600 -95,386 -91%
National Bank of Canada
14
National Bank of Canada
Quebec, Canada
$3.91K 730 -34 -4%